Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 12, 1999

View Archived Issues

Peptide immunomodulators available for licensing from Peptech

Isolex 300 and 300i cell selection system is approvable, FDA says

Health Canada approves new indication for Proleukin

New Canadian biotherapeutics company will develop SERP1 for antiinflammatory indications

Orally bioavailable agents for vascular wall hypertrophy described by Kissei

New patents issued, new developments under way at Aradigm

Shionogi patents water-soluble inhibitors of human sPLA2

Series of Na+/H+ exchange inhibitors developed at Toa Eiyo

Max Planck reports cysteine-containing compounds as MMP inhibitors

Preparation and use of new class of tachykinin antagonists disclosed by MS&D

Spanish university research team discovers new alkaloids with antitumor properties

Quinazolinones as farnesyltransferase inhibitors in early development at Janssen

China Pharmaceutical University presents new antiarrhythmic series

Novel antibiotic of the manumycin group isolated at Chinese research institute

Intravenous adenosine for MI advances to phase III

Merck KGaA acquires U.S. biochemical and reagents supplier

Ketolide antibiotic demonstrates efficacy in mice with pulmonary inflammation

Promising results reported from pilot studies of MaxDerm in several skin conditions

Preclinical studies demonstrate mechanism of action, efficacy of anti-HBV agent

ThGRF1-44 enters clinical development at Theratechnologies

FDA approves world's smallest estrogen transdermal patch

New market approvals for Zestril as Rx for renal complications of diabetes

Two Elan neurology products move closer to market in U.S.

Milestone reached in Metabasis-Sankyo diabetes collaboration

ATP citrate (pro-S)-lyase confirmed as potential therapeutic target in lipid disorders

SangStat continues to progress with generic ciclosporin formulations

Novel antiviral phenylpropenamide derivative for HBV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...